Non-bismuth quadruple therapy for first-line Helicobacter pylori eradication: A randomized study in Japan

Table 6 Frequency of adverse events

Adverse events	LACM7n = 56 (%)	LAC7n = 54 (%)	P value
Diarrhea	17 (30.1)	13 (24.1)	0.53
Taste disturbance	7 (12.5)	2 (3.7)	0.16
Loss of appetite	5 (8.9)	0 (0.0)	0.06
Heart burn	5 (8.9)	4 (7.4)	1.00
Nausea	2 (3.6)	0 (0.0)	0.50
Abdominal pain/distention	7 (12.5)	3 (5.6)	0.32
Belching	3 (5.4)	2 (3.7)	1.00
Rash	0 (0.0)	1 (1.9)	0.49
General fatigue	2 (3.6)	1 (1.9)	1.00